Hölig, Kristina
Schmidt, Helmuth
Hütter, Gero
Kramer, Michael
Teipel, Raphael
Heidrich, Katharina
Zimmer, Kristin
Heidenreich, Falk
Blechschmidt, Matthias
Torosian, Tigran
Ordemann, Rainer
Kroschinsky, Frank
Rücker-Braun, Elke
Gopsca, Laszlo
Wagner-Drouet, Eva Maria
Oelschlaegel, Uta
Schmidt, Alexander H.
Bornhäuser, Martin
Ehninger, Gerhard
Schetelig, Johannes http://orcid.org/0000-0002-2780-2981
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB 655, B7)
Article History
Received: 7 February 2020
Revised: 14 August 2020
Accepted: 2 September 2020
First Online: 7 October 2020
Change Date: 12 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-021-01523-3
Compliance with ethical standards
:
: Sanofi-Aventis provided plerixafor at no charge and financial support for anxillary research. JS—consultancy honoraria from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Molmed; lecture fees from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Novartis; research support from Genzyme, Sanofi, GSK, Novartis, AKH—consultancy honoraria from Sanofi; lecture fees from Sanofi, Janssen, and Therakos; research support from Sanofi. The remaining authors declared no conflict of interest.